Compare Merck & Co., Inc. (MRK) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? Merck & Co., Inc. trades at $146.05 (market cap $351.28B), while Norwegian Cruise Line Holdings Ltd trades at $15.58 (market cap $7.11B). The key difference: Merck & Co., Inc. is far larger — about 49.4× Norwegian Cruise Line Holdings Ltd's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Norwegian Cruise Line Holdings Ltd for 68 Days on average.
| MRK | NCLH | |
|---|---|---|
Market Cap | $351.28B | $7.11B |
Volume | 7,969,665 | 22,683,268 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $25.02 |
52-Week Low | $82.49 | $14.12 |
Typical Hold Time | 98 Days | 68 Days |
Enterprise Value | $398.04B | $21.93B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
NCLH trades at $15.57, up 3.46% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.48, beating expectations, and expects Q3 results to exceed guidance. Valuation metrics appear attractive with a P/E of 9.39 and P/S of 0.75. Revenue has grown from $4.8B in 2022 to $9.83B in 2025, though net income margin declined to 4.3% from 9.6% in 2024.
The outlook is mixed: analyst consensus is bullish with a $20.86 price target, but the company faces yield pressure and high debt levels. Investment opportunity lies in continued operational recovery and compelling valuation, while risks include Caribbean pricing pressure and significant leverage that could constrain financial flexibility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
